Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

BMI, age affect correlation between sleep and hypertension

08 Nov 2019
Sleep Apnea: A silent killer

The link between sleep duration and hypertension risk appears to be mediated by age and body mass index (BMI), a recent study has found.

Researchers performed a population-based cross-sectional survey on 130,139 adults who were asked to accomplish surveys designed to collect information about sleep duration, hypertension and BMI status. Participants were grouped into three according to sleep duration: <7 hours (short sleepers; 32 percent), 7–9 hours (64 percent) and >9 hours (long sleepers; 4 percent).  

Logistic regression analysis confirmed the link between sleep duration and hypertension. Compared to those who met the recommended hours of sleep per night, short (odds ratio [OR], 1.25, 95 percent confidence intervals [CI], 1.21–1.29) and long (OR, 1.99, 95 percent CI, 1.83–2.15) sleepers were significantly more likely to develop hypertension. After adjusting for confounders, however, the risk only remained for short sleepers.

Age emerged as an important modifying factor. Among short sleepers, those in the 18–44-year age group were more likely to have hypertension (OR, 1.25, 95 percent CI, 1.16–1.35) than participants 65 years (OR, 1.09, 95 percent CI, 1.01–1.17). This effect was absent in middle-aged (aged 45–64 years) adults.

Long sleep, on the other hand, was associated with increased hypertension risk in the elderly (aged 65 years; OR, 1.45, 95 percent CI, 1.28–1.65) relative to participants in middle-age (OR, 1.24, 95 percent CI, 1.05–1.46). Long sleep was unrelated to hypertension risk in the youngest age group.

Disaggregation according to BMI also revealed important differences. Short sleep, for instance, was more predictive of hypertension in adults with normal BMI than in obese counterparts. The opposite was true for long sleep, which increased the risk of hypertension more strongly in overweight participants.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.